White Paper

Rescheduling Questions: How the Marijuana Landscape Could Soon Change

While the recent rescheduling of marijuana mainly applies to medical products and not recreational use, it does introduce significant implications for clinical research, drug development, and downstream utilization in patient care.

White Paper Summary

The Department of Justice (DOJ) and the DEA recently rescheduled marijuana, moving FDA-approved and state-regulated medical marijuana products to Schedule III of the Controlled Substances Act.

For years, there has been much discussion regarding the rescheduling of marijuana. As a Schedule I controlled substance, marijuana faced various restrictions surrounding clinical research, drug development, medical utilization and reimbursement, and more. This monumental change now makes it important for stakeholders to assess policy, utilization and operational impacts.

It is worth noting that this change effectively reschedules only medical marijuana and not recreational marijuana. At the federal level, marijuana is still illegal and subject to strict controls, though regulatory wheels are moving to evaluate a potential broader rescheduling.

 

For more content like this from Healthesystems visit their RxInformer clinical journal website.

Healthesystems is a leading provider of Pharmacy Benefit Management (PBM) & Ancillary Benefits Management programs for the workers' compensation industry.

More from Risk & Insurance